---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-105706"
form_type: "8-K"
ticker: "DTIL"
cik: "0001357874"
company_name: "PRECISION BIOSCIENCES INC"
filed_at: "2024-09-12T23:59:59+00:00"
generated_at: "2026-05-31T05:12:08.870204+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Precision BioSciences names Murray Abramson SVP Clinical Development, John Fry as HBV Advisor; CMO List retires

## Summary
- Alan List, CMO, retiring effective Sept 13, 2024; will transition to clinical consultant at $325/hour and remain on SAB.
- Murray Abramson, MD MPH, appointed SVP Head of Clinical Development; previously SVP at Tempus, VP at Biogen, roles at Merck.
- John Fry appointed Strategic Clinical Advisor for hepatitis; former EVP at Aligos Therapeutics, Head Early Development at Alios.
- Leadership changes strengthen team for PBGENE-HBV (hepatitis B) with anticipated Phase 1 data milestones in 2025.

## SEC filing metadata
- accession: 0000950170-24-105706
- form_type: 8-K
- ticker: DTIL
- cik: 0001357874
- company_name: PRECISION BIOSCIENCES INC
- filed_at: 2024-09-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1357874/000095017024105706/0000950170-24-105706-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1357874/000095017024105706/dtil-20240909.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-105706
- JSON: https://secwatch.observer/filing/0000950170-24-105706.json
- Plain text: https://secwatch.observer/filing/0000950170-24-105706.txt

## Key facts
- Executive change
  Alan List departed as Chief Medical Officer at PRECISION BIOSCIENCES INC.
  - Action: will be retiring
  - Role: Chief Medical Officer
  source text: On September 9, 2024, Alan List, M.D., the Company’s Chief Medical Officer, notified Precision BioSciences, Inc. (the “Company”) that he will be retiring from the Company, effective September 13, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1357874/000095017024105706/0000950170-24-105706-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.